Buy or sell Nimbus Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Nimbus Therapeutics Stock

Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.

About Nimbus Therapeutics Stock

Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.

Funding History

April 2010$3.5M
March 2011$1.5M
June 2011$24.0M
March 2015$43.0M
June 2018$65.0M

Management

Chief Business Officer

Jeb Keiper

Head of Chemistry

Ronald Wester

Co-Founder

Bruce Booth

Co-Founder and Director

Ramy Farid

CEO

Donald Nicholson

Head of Nimbus Tyk2

Craig Masse

Chief Scientific Officer

Rosana Kapeller

Head of Nimbus

Donna Romero

Head of Preclinical and Early Development

William Westlin

Head of Nimbus ACC

Geraldine Harriman

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Nimbus Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 100K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo